TAVR for Bicuspid Aortic Stenosis: Is This the Next Frontier?

The approach is feasible but more data are needed before it becomes standard.

Transcatheter aortic valve replacement (TAVR) is approved for high-risk patients with severe, symptomatic aortic stenosis (AS); appears to be heading toward approval soon for intermediate-risk patients; and is undergoing evaluation in low-risk subjects. Many of these low-risk patients will have congenitally bicuspid valves with calcification occurring at a younger age than is typical in senile AS; patients with bicuspid valves were excluded from the randomized trials. In this retrospective, multicenter trial, the clinical outcomes of the SAPIEN 3 TAVR system were evaluated in 51 patients with bicuspid valvular AS (mean age, 76; 53% women).

The average Society of Thoracic Surgeons score for predicted risk of 30-day mortality was 5.2%. The mea…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)